Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 5/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556294 | 0.86 | NPC1 (0.47) | NPC1RAB9APOLBP2RX7ELANE | |
| SCHEMBL6556281 | 0.82 | NPC1 (0.46) | NPC1RAB9APOLBELANEMAOB | |
| SCHEMBL2801105 | 0.81 | ELANE (0.62) | NPC1RAB9APOLBELANEMAOB | |
| SCHEMBL7297137 | 0.80 | NPC1 (0.48) | NPC1RAB9APOLBP2RX7ELANE | |
| SCHEMBL6558269 | 0.80 | ELANE (0.51) | ELANECTRC | |
| SCHEMBL6558328 | 0.80 | ELANE (0.59) | ELANECTRC | |
| SCHEMBL27467966 | 0.79 | NPC1 (0.50) | NPC1RAB9APOLBP2RX7ELANE | |
| SCHEMBL6805338 | 0.79 | IDO1 (0.50) | NPC1RAB9APOLBSMN1; SMN2LMNA | |
| SCHEMBL6805017 | 0.78 | SMN1; SMN2 (0.46) | NPC1RAB9APOLBP2RX7ELANE | |
| SCHEMBL7276630 | 0.78 | ELANE (0.50) | NPC1RAB9AELANEMAOBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | claimed |
| EP-0826671-B1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-5948785-A | USEFUL AS CHYMASE INHIBITORS AND CAN BE EFFECTIVE FOR THE PROPHYLAXIS AND TREATMENT OF VARIOUS DISEASES CAUSED BY CHYMASE, SUCH AS THOSE CAUSED BY ANGIOTENSIN II. | THE GREEN CROSS CORPORATION (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0826671-A1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | THE GREEN CROSS CORPORATION (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | DPYD, NUDT1, UMPS | NPC1 1638/4885RAB9A 2244/4885POLB 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.